2014-004248-36
The administration of adjuvanted Trivalent Influenza Vaccine (aTIV) has come to result in a more immunogenic and effective response compared with conventional influenza vaccines in elderly and adults.
Novartis Pharma Services AG·EU Clinical Trials Register
Study focus
- Disease/Condition
- Influenza
Sponsor & location
- Primary sponsor
- Novartis Pharma Services AG
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
1. Percentage of subjects reporting solicited local and systemic AEs from day 1 to
ICD-10 classifications
Influenza and pneumoniaInfluenza due to identified seasonal influenza virusInfluenza with other manifestations, seasonal influenza virus identifiedInfluenza with pneumonia, seasonal influenza virus identifiedInfluenza due to identified zoonotic or pandemic influenza virus
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2014-004248-36
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2014-004248-36 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma Services AG and is currently status unknown. The study focuses on Influenza.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.